PharmaCyte Biotech, Inc.
PMCBNasdaqCIK 1157075HealthcareFiscal year ends Apr 30
Latest reported revenue, Q1 FY2027$0Revenue, Q1 FY2027, three months to 2026-07-31$0. XBRL concept
us-gaap:Revenues. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figureThree months to Jul 31, 2026, from the 10-Q filed Sep 14, 2026.Latest quarter: Q1 FY2027
Three months to Jul 31, 2026, against the same quarter a year earlier.
- Revenue$0Revenue, Q1 FY2027, three months to 2026-07-31$0. XBRL concept
us-gaap:Revenues. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figureSign changed from a year earlier - Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Diluted EPS−$0.54Diluted EPS, Q1 FY2027, three months to 2026-07-31−$0.54 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure+56.1% on a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q2 FY20252024-10-31 | Q3 FY20252025-01-31 | Q4 FY20252025-04-30 | Q1 FY20262025-07-31 | Q2 FY20262025-10-31 | Q3 FY20262026-01-31 | Q4 FY20262026-04-30 | Q1 FY20272026-07-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $ | 0.0Revenue, Q2 FY2025, three months to 2024-10-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure | 0.0Revenue, Q3 FY2025, three months to 2025-01-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure | 0.0Revenue, Q4 FY2025, three months to 2025-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure | 0.0Revenue, Q1 FY2026, three months to 2025-07-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure | 0.0Revenue, Q2 FY2026, three months to 2025-10-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure | 0.0Revenue, Q3 FY2026, three months to 2026-01-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure | 0.0Revenue, Q4 FY2026, three months to 2026-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-07-29, accession 0001683168-26-005836. Derived: 12-month figure less the 9-month figure.Report this figure | 0.0Revenue, Q1 FY2027, three months to 2026-07-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Net margin | % | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Diluted EPS | $ per share | (0.39)Diluted EPS, Q2 FY2025, three months to 2024-10-31−$0.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure | (0.44)Diluted EPS, Q3 FY2025, three months to 2025-01-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure | not reported (Diluted EPS not reported) | (1.23)Diluted EPS, Q1 FY2026, three months to 2025-07-31−$1.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure | (1.24)Diluted EPS, Q2 FY2026, three months to 2025-10-31−$1.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-12-18, accession 0001683168-25-009259.Report this figure | (0.17)Diluted EPS, Q3 FY2026, three months to 2026-01-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-03-17, accession 0001683168-26-001917.Report this figure | not reported (Diluted EPS not reported) | (0.54)Diluted EPS, Q1 FY2027, three months to 2026-07-31−$0.54 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-09-14, accession 0001683168-26-007106.Report this figure | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20222022-04-30 | FY20232023-04-30 | FY20242024-04-30 | FY20252025-04-30 | FY20262026-04-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $ | 0.0Revenue, FY2022, twelve months to 2022-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2023-07-31, accession 0001683168-23-005175.Report this figure | 0.0Revenue, FY2023, twelve months to 2023-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2024-08-13, accession 0001683168-24-005575.Report this figure | 0.0Revenue, FY2024, twelve months to 2024-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2025-08-11, accession 0001683168-25-005821.Report this figure | 0.0Revenue, FY2025, twelve months to 2025-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure | 0.0Revenue, FY2026, twelve months to 2026-04-30$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Net margin | % | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Diluted EPS | $ per share | (0.27)Diluted EPS, FY2022, twelve months to 2022-04-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-07-31, accession 0001683168-23-005175.Report this figure | (0.22)Diluted EPS, FY2023, twelve months to 2023-04-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-08-13, accession 0001683168-24-005575.Report this figure | (1.80)Diluted EPS, FY2024, twelve months to 2024-04-30−$1.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-08-11, accession 0001683168-25-005821.Report this figure | 3.19Diluted EPS, FY2025, twelve months to 2025-04-30$3.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure | (2.77)Diluted EPS, FY2026, twelve months to 2026-04-30−$2.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-07-29, accession 0001683168-26-005836.Report this figure | |
| Free cash flow | $ | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 2026-06-30 | $218.2k | 283,381 | Reduced−76,166 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2026-06-30 | $95.7k | 124,247 | Reduced−71,413 | |
| CITADEL ADVISORS LLC | 2026-06-30 | $66.3k | 86,100 | Call | Reduced−74,100 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $43.7k | 56,778 | Added+5,311 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-06-30 | $34.5k | 44,853 | New+44,853 | |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $29.3k | 37,987 | Reduced−18,513 | |
| XTX Topco Ltd | 2026-06-30 | $26.3k | 34,180 | Reduced−18,182 | |
| NORTHERN TRUST CORP | 2026-06-30 | $25.1k | 32,624 | Reduced−2,977 | |
| JANE STREET GROUP, LLC | 2026-06-30 | $23.1k | 30,064 | Added+18,534 | |
| Schonfeld Strategic Advisors LLC | 2026-06-30 | $20.7k | 26,926 | Reduced−83 |
Recent filings
All 410 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1621:00 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001683168-26-007934 |
| 2026-09-1420:05 ET | 10-Q | Quarterly reportPeriod 2026-07-31 | 0001683168-26-007106 |
| 2026-07-2920:58 ET | 10-K | Annual reportPeriod 2026-04-30 | 0001683168-26-005836 |
| 2026-04-0220:19 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001683168-26-002613 |
| 2026-03-1719:49 ET | 10-Q | Quarterly reportPeriod 2026-01-31 | 0001683168-26-001917 |
| 2026-03-0910:02 ET | DEF 14A | Proxy statementPeriod 2026-03-30 | 0001683168-26-001593 |
| 2025-12-1822:04 ET | 10-Q | Quarterly reportPeriod 2025-10-31 | 0001683168-25-009259 |
| 2025-12-0522:00 ET | 8-K | 3.01 Delisting notice | 0001683168-25-008947 |
| 2025-11-1821:29 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001683168-25-008515 |
| 2025-11-1821:05 ET | 8-K/A | 9.01 Financial statements and exhibits | 0001683168-25-008512 |
Latest annual report
Form 10-K for the fiscal year ended Apr 30, 2026Filed Jul 29, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1157075
- Tickers
- PMCB
- Exchange
- Nasdaq
- SIC code
- 2836 Biological Products, (No Diagnostic Substances)
- Sector
- Healthcare
- Fiscal year ends
- Apr 30
- Incorporated in
- NV
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Former names
- NUVILEX, INC. (to 2015-01-09); EFOODSAFETY COM INC (to 2009-03-17)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.